Compare GAIA & CLNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GAIA | CLNN |
|---|---|---|
| Founded | 1988 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 105.7M | 120.6M |
| IPO Year | 1999 | N/A |
| Metric | GAIA | CLNN |
|---|---|---|
| Price | $3.35 | $6.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $9.00 | ★ $32.67 |
| AVG Volume (30 Days) | 70.9K | ★ 283.4K |
| Earning Date | 11-03-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $98,622,000.00 | $214,000.00 |
| Revenue This Year | $11.55 | N/A |
| Revenue Next Year | $11.08 | $87.58 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 14.80 | N/A |
| 52 Week Low | $2.93 | $2.28 |
| 52 Week High | $6.39 | $13.50 |
| Indicator | GAIA | CLNN |
|---|---|---|
| Relative Strength Index (RSI) | 23.16 | 33.69 |
| Support Level | $3.65 | $8.90 |
| Resistance Level | $3.89 | $9.92 |
| Average True Range (ATR) | 0.18 | 1.00 |
| MACD | -0.01 | -0.37 |
| Stochastic Oscillator | 19.35 | 3.13 |
Gaia Inc is a video streaming service and community that provides curated conscious media in primary channels; Seeking Truth provides new and enlightening perspectives for today's changing world; Transformation provides a wealth of content in the niche areas of spiritual growth, personal development, and expanded consciousness; Alternative Healing channel features content focused on food and nutrition, holistic healing, alternative and integrative medicines, and longevity, and Yoga. Geographically, it derives a majority of its revenue from the United States and also has an International presence.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.